natgillin/translations-raw huggingface dataset:
Uncommon: may affect up to 1 in 100 people • higher than normal platelet counts (thrombocytosis). 
Občasni: lahko se pojavijo pri največ 1 od 100 bolnikov • število trombocitov, večje od normalnega (trombocitoza).
• Clean the flat work surface with a new alcohol swab. 
• Delovno površino očistite z novim alkoholnim zložencem.
Patients had been diagnosed with ITP for approximately 8 years at the time of study entry. 
Ob vključitvi v študijo so imeli ITP diagnosticirano približno 8 let.
There are no or limited amount of data from the use of romiplostim in pregnant women. 
Podatkov o uporabi romiplostima pri nosečnicah ni oziroma so omejeni.
Your doctor may decide that it is best for you to inject Nplate. 
Vaš zdravnik bo morda presodil, da je najbolje, če si zdravilo Nplate injicirate sami.
After subcutaneous administration of 3 to 15 mcg/kg romiplostim, maximum romiplostim serum levels in ITP patients were obtained after 7-50 hours (median 14 hours). 
Po subkutani uporabi od 3 do 15 µg/kg romiplostima je bila največja koncentracija romiplostima v serumu pri bolnikih z ITP dosežena po 7 do 50 urah (mediano po 14 urah).
• muscles pain or weakness (myalgia); 
• bolečine v mišicah ali šibkost mišic (mialgija),
• bone marrow disorder, including increased bone marrow fibres (reticulin); 
• motnja kostnega mozga, vključno s povečanim nastajanjem vlaken kostnega mozga (retikulin),
Using: Filled syringe with measured Nplate dose and safety needle. 
Uporabite: Napolnjeno brizgo z odmerjenim odmerkom zdravila Nplate in varnostno iglo.
If someone else is giving you the injection, they can also use the outer area of the upper arms 
Če vam injekcijo da kdo drug, lahko zdravilo injicira tudi v zunanji del nadlaktov
(95% CI) (9%, 35%) (38%, 82%) (14%, 42%) (34%, 78%) (14%, 33%) (43%, 74%) p-value 
(95 % IZ) (9 %, 35 %) (38 %, 82 %) (14 %, 42 %)
• Do not set filled syringe down after removing from vial. 
• Ne odlagajte napolnjene brizge, potem ko ste jo odstranili z viale.
• bleeding under the skin (ecchymosis); 
• krvavitve pod kožo (ekhimoze),
Nplate is not recommended for use in children aged under 1 year. 
Zdravila Nplate ni priporočljivo uporabljati pri otrocih, mlajših od 1 leta.
The incidence of binding antibody post treatment was 16% (3/19) to romiplostim, of which 5.3% (1/19) were positive for neutralising antibodies to romiplostim. 
Incidenca vezavnih protiteles po zdravljenju je bila 16 % (3/19) proti romiplostimu, od katerih je bilo 5,3 % (1/19) pozitivnih za nevtralizirajoča protitelesa proti romiplostimu.
Reinitiate treatment with Nplate in accordance with dosing and administration recommendations (see sections 4.2 and 4.4). 
Ponoven začetek zdravljenja z zdravilom Nplate mora biti v skladu s priporočili za odmerjanje in dajanje (glejte poglavji 4.2 in 4.4).
Oropharyngeal pain, upper abdominal pain, rhinitis, pharyngitis, conjunctivitis, ear infection, sinusitis and peripheral swelling were additional adverse reactions observed in paediatric studies compared to those seen in adult studies. 
Orofaringealna bolečina, bolečina v zgornjem delu trebuha, rinitis, faringitis, konjuktivitis, vnetje ušesa, sinusitis in periferno zatekanje so bili dodatni neželeni učinki, ki so jih opazili v preskušanjih pri pediatričnih bolnikih v primerjavi z neželenimi učinki, opaženimi v preskušanjih pri odraslih bolnikih.
• With a short, sharp motion, push the needle into the skin. 
• S kratkim, odločnim gibom iglo zabodite v kožo.
It is important that you do not try to give yourself the injection unless you have received training from your doctor, nurse or pharmacist. 
Pomembno je, da si zdravila ne poskušate injicirati sami, dokler vas tega ne nauči vaš zdravnik, medicinska sestra ali farmacevt.
Your doctor will adjust your dose of Nplate to ensure that your platelet count does not become too high. 
Zdravnik bo odmerek zdravila Nplate prilagodil tako, da se vam število trombocitov ne bo preveč povečalo.
The most frequently used weekly dose was between 3-5 mcg/kg (25th-75th percentile respectively; median 3 mcg/kg). 
Najpogosteje uporabljeni tedenski odmerek je bil 3-5 µg/kg (vrednosti sta 25. in 75. percentil; mediana 3 µg/kg).
Nplate is administered once a week as an injection under the skin (subcutaneous). 
Zdravilo Nplate uporabljamo enkrat tedensko z injiciranjem pod kožo (subkutano injiciranje).
Check the expiry date on the self injection kit. 
Preverite datum izteka roka uporabnosti na kompletu za samoinjiciranje.
A decision on whether to discontinue breast-feeding or discontinue therapy with romiplostim should be made taking into account the benefit of breast-feeding to your child and the benefit of romiplostim therapy to you. 
Pri odločitvi o prekinitvi dojenja ali prekinitvi zdravljenja z romiplostimom je treba upoštevati korist dojenja za otroka in korist zdravljenja z romiplostimom za vas.
1 sterile safety needle. 
1 sterilno varnostno iglo.
• The clear plastic plunger rod MUST always be attached first before breaking the white tip off of the pre-filled water syringe. 
• Prozorno plastično držalo bata MORATE vedno namestiti prej, preden odlomite belo konico z napolnjene injekcijske brizge z vodo.
9/L, resume dosing with once weekly dose reduced by 1 mcg/kg 
9/l, znova začnite uporabljati zdravilo enkrat na teden v odmerku, zmanjšanem za 1 µg/kg.
If you experience a loss of response or failure to maintain a platelet response with romiplostim treatment, your doctor will investigate the reasons why including whether you are experiencing increased bone marrow fibres (reticulin) or have developed antibodies which neutralise romiplostim's activity. 
Če izgubite odziv na zdravljenje z romiplostimom ali vam z njim ni mogoče vzdrževati odziva trombocitov, bo zdravnik proučil razloge za to; med drugim bo raziskal, ali se vam je pojavilo zvišanje vlaken (retikulina) v kostnem mozgu in ali so se vam pojavila protitelesa, ki nevtralizirajo delovanje romiplostima.
Reconstitute lyophilised product and then dilute the product as described in section 6.6. 
Pripravite liofilizirano zdravilo in ga nato razredčite, kot je opisano v poglavju 6.6.
Serum concentrations of romiplostim in paediatrics with ITP were within the range observed in adult ITP subjects receiving the same dose range of romiplostim. 
Serumske koncentracije romiplostima pri pediatričnih bolnikih z ITP so bile znotraj mej, opaženih pri odraslih bolnikih z ITP, ki so prejemali enak razpon odmerka romiplostima.
Some of the adverse reactions seen in adults were reported more frequently in paediatric subjects such as cough, diarrhoea, rash, pyrexia and contusion reported very commonly (≥ 1/10) in paediatric subjects and purpura and urticaria were reported commonly (≥ 1/100 to < 1/10) in paediatric subjects. 
O nekaterih neželenih učinkih, opaženih pri odraslih bolnikih, so bolj pogosto poročali pri pediatričnih bolnikih, kot npr. kašelj, driska, pireksija in zmedenost so bili poročani zelo pogosto (≥ 1/10) pri pediatričnih bolnikih, ter purpura in urtikarija sta bili poročani pogosto (≥ 1/100 do < 1/10)) pri pediatričnih bolnikih.
The HAT pack includes materials for HCPs on how to select and train patients for self-administration of romiplostim; and for patients, in order to help them with the process of preparation and self-administration of the correct dose of romiplostim. 
Paket za usposabljanje za samoinjiciranje doma obsega gradiva za zdravnike o tem, kako izbrati in usposobiti bolnike za samoinjiciranje romiplostima, in gradiva za bolnike kot pomoč v postopku priprave in samoinjiciranja pravilnega odmerka romiplostima.
• swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema); 
• otekanje obraza, ustnic, ust, jezika ali grla, ki lahko povzroči težave pri požiranju ali dihanju
• Remove 1 mL syringe from package. 
• Vzemite 1 ml brizgo iz pakiranja.
Rescue therapies defined as any therapy administered to raise platelet counts. 
Za rešilno terapijo velja vsaka terapija, uvedena z namenom povečanja števila trombocitov.
In mice there was evidence of increased post-implantation loss. 
Pri miših so ugotavljali večje poimplantacijske izgube plodov.
• After injecting, use your thumb (or tip of your finger) to activate the pink safety cover by pushing the cover forward using the same hand until you hear and/or feel it click and lock into place over the needle. 
• Po injiciranju s palcem (ali konico kakšnega drugega prsta) aktivirajte rožnati varnostni pokrovček tako, da ga z isto roko potisnete naprej, dokler ne zaslišite in/ali začutite, da je kliknil in se je zaskočil nad iglo.
Keep the Nplate self injection kit refrigerated at 2ºC to 8ºC. 
Komplet za samoinjiciranje zdravila Nplate shranjujte v hladilniku pri temperaturi od 2 do 8 °C.
• inflammation of the sinuses (sinusitis); 
• vnetje sinusov (sinusitis),
The most serious adverse reactions that may occur during Nplate treatment include: reoccurrence of thrombocytopenia and bleeding after cessation of treatment, increased bone marrow reticulin, thrombotic/thromboembolic complications, medication errors and progression of existing MDS to AML. 
Najbolj resni neželeni učinki, ki se lahko pojavijo med zdravljenjem z zdravilom Nplate, vključujejo: ponoven pojav trombocitopenije in krvavenje po prenehanju zdravljenja, zvišanje retikulina v kostnem mozgu, trombotične/tromboembolične zaplete, napake pri uporabi zdravila in napredovanja bolezni iz MDS v AML.
It is unknown whether romiplostim/metabolites are excreted in human milk. 
Ni znano, ali se romiplostim/presnovki izločajo v materino mleko.
• In adults, future dose adjustments are based on changes in platelet counts only. 
• Pri odraslih bolnikih nadaljnje prilagoditve odmerka temeljijo samo na spremembi števila trombocitov.
The median (Q1, Q3) average weekly dose was 4.82 mcg/kg (1.88 mcg/kg, 8.79 mcg/kg). 
Mediana (Q1, Q3) povprečnega tedenskega odmerka je bila 4,82 µg/kg (1,88 µg/kg, 8,79 µg/kg).
Patients had been diagnosed with ITP for approximately 2 years at the time of study entry. 
Ob vključitvi v študijo so imeli ITP diagnosticirano približno 2 leti.
The risk of blood clotting may also be increased if you: have liver problems; are elderly (≥ 65 years); are bedridden; have cancer; are taking the contraceptive pill or hormone replacement therapy; have recently had surgery or suffered an injury; are obese (overweight); are a smoker. 
Vaše tveganje krvnih strdkov je lahko večje tudi: če imate težave z jetri, če ste starejša oseba (≥ 65 let), če ste priklenjeni na posteljo, če imate raka, če jemljete kontracepcijske tablete ali hormonsko nadomestno zdravljenje, če ste pred kratkim imeli operacijo ali kakšno poškodbo, če ste debeli (čezmerno težki), če kadite.
Pull back on the pink safety cover toward the syringe and away from the needle. 
Potegnite rožnati varnostni pokrovček k brizgi in proč od igle.
Among the 75 subjects who received at least one dose of SOC, the total median exposure to SOC was 51 weeks and ranged from 0.4 to 52 weeks. 
Med 75 bolniki, ki so prejeli vsaj en odmerek standardne oskrbe, je bila celotna mediana izpostavljenosti standardni oskrbi 51 tednov in je segala od 0,4 do 52 tednov.
• Do not use components that have evidence of tampering or damage. 
• Ne uporabite posameznih naštetih elementov, na katerih so vidni znaki poseganja vanje ali okvare.
• Do not force the water into the vial. 
• Ne potiskajte vode v vialo s silo.
Volume of sterile water for injection 
Količina sterilne vode za injekcije
Injecting Nplate yourself 
Če si sami injicirate zdravilo Nplate
Results from pivotal placebo-controlled studies 
Rezultati ključnih s placebom kontroliranih študij
If you have very high blood platelet counts this may increase the risk of blood clotting. 
Če imate zelo veliko trombocitov v krvi, lahko to poveča tveganje za nastanek krvnih strdkov.
Treatment with romiplostim should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after four weeks of romiplostim therapy at the highest weekly dose of 10 mcg/kg. 
Zdravljenje z romiplostimom je treba prekiniti, če se število trombocitov po štirih tednih zdravljenja z največjim tedenskim odmerkom romiplostima 10 µg/kg ne poveča dovolj, da bi preprečilo klinično pomembne krvavitve.
• blood clot in a lung artery (pulmonary embolism); 
• krvni strdek v pljučni arteriji (pljučna embolija),
Therefore if your doctor suspects that you have been given more Nplate than you should, it is recommended that you are monitored for any signs or symptoms of side effects and that you are given appropriate treatment immediately. 
Če torej zdravnik sumi, da ste dobili večji odmerek zdravila Nplate, kot bi smeli, je priporočljivo, da vas kontrolira glede znakov in simptomov neželenih učinkov in da ste takoj deležni ustreznega zdravljenja.
The pharmacokinetics of romiplostim involved target-mediated disposition, which is presumably mediated by TPO receptors on platelets and other cells of the thrombopoietic lineage such as megakaryocytes. 
Farmakokinetika romiplostima vključuje tarčno posredovano odstranjevanje, ki domnevno poteka preko receptorjev TPO na trombocitih in drugih celicah trombopoetske vrste, npr. na megakariocitih.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from romiplostim therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z romiplostimom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
• Inject the prescribed dose subcutaneously as directed by your doctor, nurse or pharmacist. 
• Predpisani odmerek injicirajte pod kožo po navodilu, ki ste ga dobili od vašega zdravnika, medicinske sestre ali farmacevta.
Romiplostim has no amino acid sequence homology to endogenous TPO. 
Aminokislinsko zaporedje romiplostima ni homologno endogenemu TPO.
9/L) and treatment interruption (400 x 10 9/L) may be considered according to medical judgement. 
9/l) in prekinitev zdravljenja (400 x 10
Romiplostim is an Fc-peptide fusion protein (peptibody) that signals and activates intracellular transcriptional pathways via the TPO receptor (also known as cMpl) to increase platelet production. 
Romiplostim je Fc-peptidna fuzijska beljakovina (peptidno telo), ki signalizira in aktivira znotrajcelične transkripcijske poti preko receptorjev TPO (te receptorje imenujemo tudi cMpl), in tako poveča nastajanje trombocitov.
Reconstitute lyophilised product as described in section 6.6. 
Pripravite liofilizirano zdravilo kot je opisano v poglavju 6.6.
Therefore if your doctor suspects that you have been given less Nplate than you should, it is recommended that you are monitored for any signs or symptoms of side effects and that you are given appropriate treatment immediately. 
Če torej zdravnik sumi, da ste dobili manjši odmerek zdravila Nplate, kot bi morali, je priporočljivo, da vas kontrolira glede znakov in simptomov neželenih učinkov in da ste takoj deležni ustreznega zdravljenja.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 25ºC or 24 hours in a refrigerator (2ºC - 8ºC), protected from light. 
Če ni uporabljeno takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika; čas običajno ne sme biti daljši od 24 ur pri 25 °C ali 24 ur v hladilniku (2 °C do 8 °C), zaščiteno pred svetlobo.
Romiplostim is produced by recombinant DNA technology in Escherichia coli (E. coli). 
Romiplostim je pridobljen v Escherichia coli (E. coli) s tehnologijo rekombinantne DNA.
Patients should be closely monitored for a decrease in platelet count and medically managed to avoid bleeding upon discontinuation of treatment with romiplostim. 
Bolnike morate natančno spremljati, da bi ugotovili zmanjšanje števila trombocitov, in jih ustrezno voditi, da bi preprečili krvavitve po prenehanju zdravljenja z romiplostimom.
A maximum once weekly dose of 10 mcg/kg should not be exceeded. 
Največjega odmerka 10 µg/kg enkrat na teden ne smete preseči.
Studies in animals have shown that romiplostim crossed the placenta and increased foetal platelet counts. 
Študije na živalih so pokazale, da romiplostim prehaja skozi placento in poveča število trombocitov pri plodovih.
Your doctor will decide if abnormal blood tests mean that you should have bone marrow tests or if you should stop taking Nplate. 
Zdravnik bo presodil, ali je treba zaradi nepravilnosti vaših izvidov krvi opraviti preiskave kostnega mozga in ali morate nehati uporabljati zdravilo Nplate.
The once weekly dose of romiplostim should be increased by increments of 1 mcg/kg until the patient achieves a platelet count ≥ 50 x 10 
Odmerek romiplostima enkrat na teden je treba povečevati po 1 µg/kg, dokler bolnik ne doseže števila trombocitov ≥ 50 x 10
• raised white blood cell count (leucocytosis); 
• povečano število belih krvnih celic (levkocitoza),
Immediately prepare new syringe for injection. 
Takoj pripravite novo brizgo za injiciranje.
Based on an analysis of all adult ITP patients receiving romiplostim in 4 controlled and 5 uncontrolled clinical trials, the overall subject incidence of all adverse reactions for romiplostim-treated subjects was 91.5% (248/271). 
Na podlagi analize vseh odraslih bolnikov z ITP, ki so prejemali romiplostim v 4 kontroliranih in 5 nekontroliranih kliničnih preskušanjih, je bila celotna incidenca vseh neželenih učinkov pri bolnikih, zdravljenih z romiplostimom, 91,5 % (248/271).
Draw air into syringe to the 1 mL mark 
Potegnite v brizgo zrak do oznake 1 ml
- The active substance is romiplostim. 
- Zdravilna učinkovina je romiplostim.
The maximum deliverable volume for the 250 microgram vial is 0.5 mL and for the 500 microgram vial is 1 mL. 
Največja uporabna količina iz 250 mikrogramske viale je 0,5 ml in iz 500 mikrogramske viale 1 ml.
What Nplate looks like and contents of the pack 
Izgled zdravila Nplate in vsebina pakiranja
Across all subjects, the median (Q1, Q3) percentage of months with platelet response was 93.33% (67.57%, 100.00%) and was similar across age groups. 
V skupini vseh bolnikov je znašala mediana (Q1, Q3) odstotka mesecev z odgovorom trombocitov 93,33 % (67,57 %, 100,00 %) in je bila podobna med starostnimi skupinami.
Common: may affect up to 1 in 10 people (may show up in blood or urine tests) 
Pogosti: lahko se pojavijo pri največ 1 od 10 bolnikov (lahko se pokažejo na preiskavah krvi ali urina)
Dilution is required to ensure accurate dosing. 
Za natančno odmerjanje je potrebno redčenje.
This non-linear decrease in volume of distribution is in line with the (megakaryocyte and platelet) target-mediated binding of romiplostim, which may be saturated at the higher doses applied. 
To nelinearno zmanjšanje volumna porazdelitve se sklada s tarčno posredovano vezavo romiplostima (na megakariocitih in trombocitih), ki je lahko pri večjih odmerkih zasičena.
Nplate is not recommended for use if you are pregnant unless indicated by your doctor. 
Uporaba zdravila Nplate ni priporočljiva, če ste noseči, razen če zdravnik ugotovi, da to zdravilo res potrebujete.
If your doctor has allowed you to self-inject and you forget to give yourself an injection, you should inform your doctor immediately. 
Če vam je zdravnik dovolil, da si zdravilo injicirate sami in ste si pozabili dati injekcijo, morate o tem takoj obvestiti svojega zdravnika.
Additionally, in the phase 3 pivotal studies, romiplostim did not affect the red blood cell and white blood cells lineages relative to placebo treated subjects. 
Poleg tega romiplostim v ključnih študijah 3. faze pri preiskovancih v primerjavi s placebom ni vplival na rdečo in belo celično vrsto.
If a loss of efficacy and abnormal peripheral blood smear is observed in patients, administration of romiplostim should be discontinued, a physical examination should be performed, and a bone marrow biopsy with appropriate staining for reticulin should be considered. 
Če pri bolniku pride do zmanjšanja učinkovitosti in nenormalnosti v razmazu krvi, morate uporabo romiplostima prekiniti, opraviti klinični pregled in razmisliti o biopsiji kostnega mozga z ustreznim barvanjem na retikulin.
Of those 62 subjects, 48 subjects had ITP > 12 months of duration (32 subjects received romiplostim and 16 subjects received placebo). 
Od teh 62 bolnikov je 48 bolnikov imelo ITP > 12 mesecev (32 bolnikov je prejelo romiplostim in 16 bolnikov je prejelo placebo).
Platelet count (x 10 
Število trombocitov (x 10
Romiplostim was administered to 157 subjects by subcutaneous (SC) injection once weekly starting at a dose of 3 mcg/kg, and adjusted throughout the study within a range of 1-10 mcg/kg in order to maintain platelet counts between 50 and 200 x 10 
157 bolnikom v subkutani (s.c.) injekciji enkrat na teden, uvodoma v odmerku 3 µg/kg in s prilagajanjem med celotno študijo v razponu 1-10 µg/kg, tako da so število trombocitov vzdrževali med 50 in 200 x 10
If you use less Nplate than you should 
Če ste uporabili manjši odmerek zdravila Nplate, kot bi morali
Of the 66 subjects enrolled in the study, 63 subjects had ITP > 12 months of duration. 
Od 66 vključenih bolnikov je imelo 63 bolnikov ITP > 12 mesecev.
All (100%) splenectomised patients who were receiving romiplostim were able to reduce the dose by more than 25% or discontinue the concurrent ITP medical therapies by the end of the treatment period compared to 17% of placebo treated patients. 
Vsi (100 %) splenektomirani bolniki, ki so prejemali romiplostim, so lahko do konca obdobja zdravljenja zmanjšali odmerek sočasnih zdravil za ITP za več kot 25 % ali so lahko ta zdravila celo opustili; med bolniki, ki so prejemali placebo, je bilo takšnih 17 %.
• Do not touch vial stopper or spike of vial adapter. 
• Ne dotikajte se zamaška viale ali konice nastavka za vialo.
Carton containing 1 or 4 vials of romiplostim. 
Škatla vsebuje 1 ali 4 viale z romiplostimom.
Future dose adjustments are based on changes in platelet counts only and made in 1 mcg/kg increments (see table below). 
Nadaljnje prilagoditve odmerka morajo temeljiti zgolj na spremembi števila trombocitov in jih je treba izvajati v korakih po 1 µg/kg (glejte preglednico spodaj).
Localised infection Nasopharyngitis 
gripa lokalizirana okužba nazofaringitis
• Do make sure all air bubbles are removed from the syringe. 
• Prepričajte se, da so vsi zračni mehurčki odstranjeni iz brizge.
Of these 9 subjects, 2 subjects had pre-existing binding non-neutralising antibodies to TPO. 
Od teh 9 bolinkov sta 2 bolnika imela že obstoječa vezavna ne nevtralizirajoča protitelesa proti TPO.
Patients (≥ 18 years) were randomised in a 2:1 ratio to receive a starting dose of romiplostim 1 mcg/kg or placebo. 
Bolnike (stare ≥ 18 let) so v razmerju 2:1 randomizirali na skupino, ki je prejemala začetni odmerek 1 µg/kg romiplostima in skupino, ki je prejemala placebo.
Post implantation loss and a slight increase in peri-natal pup mortality also occurred in animal studies (see section 5.3). 
V študijah na živalih so ugotovili tudi poimplantacijske izgube in rahlo večjo perinatalno umrljivost mladičev (glejte poglavje 5.3).
• Do not shake the vial. 
• Ne stresajte viale.
• Do not touch the top of vial adapter. 
• Ne dotikajte se zgornjega dela nastavka za vialo.
Medication Errors 
Napake pri uporabi zdravila
• Once all air bubbles are removed and syringe is filled with your correct dose, twist off syringe from vial adapter. 
• Ko so vsi zračni mehurčki odstranjeni in je brizga napolnjena s pravilnim odmerkom, odvijte brizgo iz nastavka za vialo.
Do rotate the site for each injection. 
Krožno menjajte mesta za vsako posamezno injiciranje.
• Draw air into syringe to 1 mL marking. 
• Potegnite v brizgo zrak do oznake 1 ml.
• Do not pull the plunger out of the back of the syringe. 
• Ne izvlecite bata ven iz zadnjega dela brizge.
Blood pressure increased Blood lactate dehydrogenase increased Body temperature increased Weight decreased Weight increased 
Preiskave zvišan krvni tlak zvišanje laktat-dehidrogenaze v krvi zvišanje telesne temperature zmanjšanje telesne mase povečanje telesne mase